Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Galmed Pharmaceuticals Q2 EPS $(0.63) Beats $(0.83) Estimate

Author: Benzinga Newsdesk | August 28, 2025 08:36am
Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.83) by 24.1 percent. This is a 61.82 percent increase over losses of $(1.65) per share from the same period last year.

Posted In: GLMD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist